2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

5794 Precog PrE1005 randomized phase 3 trial of belantamab mafodotin or daratumumab in combination with bortezomib, lenalidomide and dexamethasone for newly diagnosed multiple myeloma – trial in progress

Shaji Kumar, MD, Sagar Lonial, MD, FACP2, Zihan Wei, MSH3, S. Vincent Rajkumar, MD4
1 Mayo Clinic, Rochester, Minnesota, United States
2 Emory University, Atlanta, Georgia, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Mayo Clinic, Rochester, Minnesota, United States

Background: Quadruplet regimens with an anti-CD38 monoclonal antibody, immunomodulatory drug (IMiD) and a proteasome inhibitor (PI) have become the standard approach for newly diagnosed multiple myeloma (NDMM) irrespective of the transplant intent. BCMA has become an important therapeutic target in MM having been successfully targeted through several mechanisms including T-cell engagement through CART or CD3 bispecific antibodies as well as antibody drug conjugates (ADC). In the DREAM 7 trial, in the setting of relapsed MM, belantamab mafodotin (Bela) was shown to be superior to daratumumab when combined with bortezomib and dexamethasone. Given these results, PrECOG PrE1005 (NCT07285239) is designed to explore if we can replace daratumumab in the setting of NDMM with Bela, in the commonly used daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) regimen.

Patients and treatment: We will include patients with NDMM, 18-80 years of age, considered ineligible for autologous stem cell transplantation (ASCT) by the treating physician because of their age (≥ 70 years) or aged 18 - 70 years with the presence of underlying medical conditions that preclude ASCT, OR transplant-eligible and refusing stem-cell transplantation until first relapse or later (transplant deferred). Patients require adequate organ function, measurable disease and an ECOG Performance Status (PS) of 0-2. The study has a dual primary endpoint – (1) To evaluate if the combination with bortezomib, lenalidomide and dexamethasone (BVRd) will achieve superior rates of minimal residual disease (MRD) negativity compared to DVRd when used as primary treatment of NDMM in patients not undergoing ASCT in first line and (2) To evaluate whether BVRd compared to DVRd will have a superior efficacy measured by progression-free survival in this setting. Secondary endpoints include MRD negativity at 12 months, sustained MRD negativity, overall survival, overall response rate, adverse events and patient reported outcomes compared among the treatment arms. All efficacy assessments will be adjudicated by an independent IRC. Patients will be randomized 1:1 to receive either Belantamab Mafodotin: 1.9 mg/kg IV administered Q8W for first 24 weeks (Cycles 1-3 Q8W), then 1.9 mg/kg (Cycles 4+ Q12W) or Daratumumab: 1800 mg SC administered weekly from Week 1-8 (Cycles 1 and 2), Q2W from Week 9-24 (Cycles 3-6), and Q4W from Week 25 (Cycles 7+) onwards. Both regimens will include standard VRd regimen given in 4-week cycles. Patients will require an eye exam prior to belantamab dosing as per current REMS. Dose modifications as per label for each of the drugs will be utilized.

Statistical design: This study will enroll 500 NDMM participants, targeting 320 standard risk and 180 high risk participants to create a population enriched for IMWG-IMS high risk disease features.  Accrual is expected to be completed after 26 months for the approximately 400 participants with both risk status and after a further 25 months for the additional approximately 100 high risk participants. A total alpha of one-sided 2.5% will be split between the dual-primary endpoints with 0.75% assigned to superiority of MRD negativity and 1.75% assigned to superiority of PFS. Secondary endpoints will include OS, CR or better, VGPR or better, ORR, DOR, 12-month MRD, sustained MRD, frequency and severity of adverse events, corneal events, and patient reported outcomes.   

Shaji Kumar, MD: Allogene - Research Funding; Merck - Research Funding; Janssen Oncology - Research Funding; Gracell Bio - Research Funding; Telogenomics - Research Funding; Molecular Templates - Research Funding; Bristol Myers Squibb/Celgene - Research Funding; Novartis - Research Funding; Takeda - Research Funding; Astra Zeneca - Research Funding; Roche-Genentech - Research Funding; Roche - Research Funding; AstraZeneca - Research Funding; AbbVie - Research Funding; Bristol Myers Squibb - Research Funding; Amgen - Research Funding; KITE - Research Funding; Oricell - Research Funding; CARSgen Therapeutics - Research Funding; GSK - Research Funding; Adaptive - Research Funding; Celgene - Research Funding; Regeneron Pharmaceuticals, Inc. - Research Funding; Sanofi - Research Funding; Epizyme - Consultancy (Includes expert testimony); Seimens - Consultancy (Includes expert testimony); Monte Rosa Therapeutics - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Antengene - Consultancy (Includes expert testimony); Bristol Myers Squibb/Celgene - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); KITE - Consultancy (Includes expert testimony); GLH Pharma - Consultancy (Includes expert testimony); BeiGene - Consultancy (Includes expert testimony); Adaptive - Consultancy (Includes expert testimony); CVS Caremark - Consultancy (Includes expert testimony); Moderna - Consultancy (Includes expert testimony); bluebird bio - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Arcellx - Consultancy (Includes expert testimony); Trillium - Consultancy (Includes expert testimony); K36 - Consultancy (Includes expert testimony); Roche-Genentech - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Oncopeptides - Consultancy (Includes expert testimony); Secura Bio - Consultancy (Includes expert testimony); Regeneron Pharmaceuticals, Inc. - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Janssen Oncology - Consultancy (Includes expert testimony); Loxo Oncology - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); BD Biosciences - Consultancy (Includes expert testimony)